InNetwork, the Halifax marketing startup that helps clients spread their messages through influencers, has been acquired by Barrie, Ont.-based gShift.

GShift announced the all-stock deal in a statement Monday, but declined to place any value on the transaction or say what proportion of the enlarged company will be held by InNetwork shareholders.

GShift was founded in 2009 by Krista LaRiviere and Chris Adams to enhance search engine optimization through big data and predictive analytics. It has now chosen to merge with InNetwork, which uses a network of influencers to help clients amplify

Halifax’s Volta Labs has named Jesse Rodgers, the founding director of both Velocity and the Creative Destruction Lab, as its new CEO.

The startup house, which offers office space and mentoring to tech statups, has been looking for a CEO since last summer. With the hiring of Rogers, Executive Director Melody Pardoe will become the organization’s Chief Operating Officer.

“We’re entering into our

A new Charlottetown firm that helps game and app developers increase income has tripled its staff in six months and plans to double it again by Canada Day.

As it is now structured, RevIQ is more a service company than a conventional product-based startup, and its nine-member team helps game and app developers use their data to develop more successful sales strategies.

The problem the company

Atlantic Canada last week hosted a flurry of youth and student entrepreneurship events, with hundreds of participants and cash prizes totaling thousands of dollars.

The highest profile event was YES Atlantic, or the Youth Entrepreneur Summit, in Fredericton, which attracted about 300 delegates from across the region. But there were also student pitching events in Fredericton and Wolfville, and

Today in Job of the Week, we are featuring an opening for Manager of Technical Development at Sequence Bio of St. John’s.

Founded in 2013, Sequence works with partners to analyze vast sets of data from gene pools to get a deeper understanding of which people are at the greatest risk of contracting a disease. It recently signed an agreement with Memorial University to use the university’s genetic

Agile Sensor Technologies Inc., a St. John’s maker of components for the robotics industry, has landed six figures in funding from and a partnership agreement with Gaitech International Limited of Shanghai, China.

Agile CEO Brian Terry said in an interview Thursday that the Chinese company has provided seed funding for his startup, which grew out of a research project at Memorial University of

So Maclean’s magazine has touched quite a nerve in New Brunswick.

The national weekly this month published an article with the apocalyptic title, “Can anything save New Brunswick?”

As expected, it catalogued a litany of problems, from the aging population to French-English friction to an economy that’s “in free fall.”

And as expected, New Brunswickers reacted to the article with indignation, expressed pointedly in traditional and social media. “New Brunswick’s economy isn’t in ‘free fall.’ It’s in transition,” countered the online business publication Huddle. It highlighted that

Three leading New Brunswick researchers will be honoured in Fredericton next Wednesday at the R3 Gala, which celebrates the innovations of the province’s top applied researchers.

They are: Liuchen Chang, NSERC Chair of Environmental Design Engineering at the University of New Brunswick in Fredericton; Alain Doucet, Chief of Operations at the Metal Innovation and Technology Transfer Center

A Halifax company has launched a $500,000 to $800,000 crowdfunding campaign to test a revolutionary form of wind turbine that could improve the economics of wind power.

Lux Wind Turbines is raising money so it can build a test version of its new product, and send it to trials at the Wind Energy Institute of Canada in P.E.I. If the nine-month trials prove successful, the company believes its

Sackville, N.B.-based Soricimed Biopharma Inc., a clinical-stage pharmaceutical company developing peptide-based cancer therapeutics, has won a key regulatory approval from the Food and Drug Administration in the U.S.

The company said in a statement the FDA has granted orphan-drug designation to Soricmed’s flagship compound SOR-C13 for the treatment of ovarian cancer. Orphan drug status qualifies Soricimed for various development incentives, including tax credits and reduced filing fees for clinical trials undertaken in the U.S.  If approved for commercialization by the FDA, SOR-C13 may